Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma

Abstract

PurposeHepatocellular carcinoma (HCC) is one of the most aggressive malignancies. Recently, the overexpression of programmed cell death 1 (PD-1) and PD-1 ligand 1 (PD-L1) has been shown to correlate with poor prognosis in many cancers. However, the expression of PD-L1 or PD-1 ligand 2 (PD-L2) and clinical outcomes have not been fully investigated in HCC.Materials and MethodsFormalin-fixed paraffin-embedded samples were obtained from 85 patients with HCC who underwent surgery. The expression of PD-Ls (PD-L1, PD-L2) was evaluated by immunohistochemical analysis.ResultsThe proportion of high expression groups of PD-L1 and PD-L2 was 27.1% and 23.5%, respectively. Univariate analysis revealed that tumor size (p < 0.001), histological differentiation (p=0.010), PD-L1 expression (p < 0.001), and PD-L2 expression (p=0.039) were significant prognostic factors of overall survival in patients with HCC. Multivariate analysis revealed that overall tumor size (hazard ratio [HR], 4.131; 95% confidence interval [CI], 2.233 to 7.643; p < 0.001 and HR, 3.455; 95% CI, 1.967 to 6.067; p < 0.001) and PD-L1 expression (HR, 5.172; 95% CI, 2.661 to 10.054; p < 0.001 and HR, 3.730; 95% CI, 1.453 to 9.574; p=0.006) were independent prognostic values for overall and disease-free survival. Patients with high expression of PD-Ls had a significantly poorer survival than those with low expression (p < 0.001, p=0.034).ConclusionThe overexpression of PD-Ls in HCC patients is correlated with survival and tumor recurrence. Further evaluation of PD-1 and PD-Ls as therapeutic targets and predictive biomarkers for HCC is warranted.

Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade

“…Cancer immunotherapy with immune-checkpoint inhibitors (ICI) targeting PD-1 or CTLA-4 has demonstrated a potent and durable therapeutic efficacy and emerged as a new weapon in the war on cancer (1)(2)(3)(4)(5)(6). However, the clinical efficacy of ICIs is confined to tumors with a T cell-inflamed tumor microenvironment (TME; refs.…”

494 PD1-positive tumor-infiltrating lymphocytes are associated with poor clinical outcome after pulmonary metastasectomy for colorectal cancer

“…22 PD-L2 has also been shown to be expressed by some solid cancers as endometrium cancer and hepatocellular cancer. 23,24 In our patients we did not find PD-L2 positive cells in the lymphocytic infiltrate and only insignificant expression on tumor cells. We therefore, excuded PD-L2 from further analysis, since its impact on tumor biology and immunosurveillance can be considered minimal.…”

Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors

“…The clinical relevance of the PD‐1/PD‐L1 pathway has been demonstrated in a range of solid tumors following the therapeutic success of PD‐1 and PD‐L1 checkpoint blockade, with beneficial outcomes associated with mutational burden of TC, presence of tumor‐infiltrating immune cells, and PD‐L1 expression . Overexpression of PD‐L1, in particular, has been associated with poor prognosis in different tumor types and thus represents a rational target for cancer immunotherapy …”

“…4 Overexpression of PD-L1, in particular, has been associated with poor prognosis in different tumor types and thus represents a rational target for cancer immunotherapy. [5][6][7] In addition to its membrane expression, PD-L1 has a soluble form (sPD-L1) that has been shown to have PD-1-binding capacity, with its concentration in plasma correlating with tumor aggressiveness and outcome in different tumor types. [8][9][10][11] A recent meta-analysis of patients with solid tumors confirmed that high circulating concentrations of sPD-L1 predicted shorter OS, indicating that a high sPD-L1 level may serve as a prognostic biomarker.…”